In this expert interview, Dr. Greg Kalemkerian shares practical, real-world guidance on managing small cell lung cancer (SCLC) — from frontline therapy to relapse, supportive care, and emerging research.
Key Takeaways
- Limited-Stage SCLC: Concurrent platinum–etoposide chemoradiation remains standard, with durvalumab consolidation, now part of care for eligible patients.
- Extensive-Stage SCLC: Carboplatin/etoposide plus atezolizumab or durvalumab followed by maintenance immunotherapy is the standard approach.
- Myelosuppression Management: Routine G-CSF is not required upfront; dose adjustments are often preferred. Use growth factors selectively for high-risk or complicated cases.
- Neuropathy Prevention: Prefer carboplatin over cisplatin in higher-risk patients; early switch if neuropathy develops.
- Brain Management: MRI surveillance is often preferred over PCI in extensive-stage disease; careful patient selection is critical.
- Paraneoplastic Syndromes: SIADH occurs in ~5–10%; neurologic syndromes are rare but clinically significant. Avoid immunotherapy in autoimmune neurologic conditions (e.g., Lambert-Eaton)